



Department of Health Care Finance
441 Fourth Street NW
Main Street Conference Room 1028 (10th Floor)
Washington, DC 20001



**PHARMACY & THERAPEUTICS
COMMITTEE MEETING**

**December 5th, 2019
Time: 2:30 PM – 5:30 PM**

- | | |
|--|---|
| 1) Call to Order | Charlene Fairfax, RPh |
| 2) Minutes of Previous Meeting | Charlene Fairfax, RPh |
| 3) Comments from Interested Parties* | Gidey Amare, RPh, MS |
| 4) Clinical Drug Class Reviews | Zakia Al-Amin, PharmD, BCACP RPh
Ronald E. Kavanagh, BSP Pharm, PharmD, PhD, RPh |
| Angiotensin Modulator Combinations | Hepatitis B Agents |
| Angiotensin Modulators | Hepatitis C Agents |
| Antianginal Agents (Ranexa) | HIV and AIDS Treatments |
| Antibiotics, Topical | Immunomodulators, Atopic Dermatitis |
| Anticoagulants | Immunomodulators, Topical |
| Antihypertensives, Sympatholytics | Lipotropics, Others |
| Antipsoriatics, Oral | Lipotropics, Statins |
| Antipsoriatics, Topical | Methotrexate |
| Antiviral Agents, Oral (HSV & Influenza) | Oncology Agents-Breast |
| Antiviral Agents, Topical | Platelet Aggregation Inhibitors |
| Beta-Blockers | Rosacea Agents, Topical |
| Calcium Channel Blockers | |
| 5) Executive Session (Committee Only)** | Charlene Fairfax, RPh
MMA Representatives |
| 6) Final Recommendations of Preferred Drugs*** | MMA Representatives |
| 7) Announcement of Next Scheduled P&T Committee Meeting
Thursday March 5 th , 2020 | Charlene Fairfax, RPh |
| 8) Final Comments and Adjournment | Charlene Fairfax, RPh |

***Individuals wishing to make oral presentations to the Committee will be limited to three (3) minutes only**

****Closed Session**

*****Open Session**